Live feed
·
PRReleasevia Quantisnow
Wave Life Sciences Ltd. logo

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

ByQuantisnow·Wall Street's wire, on your screen.
WVE· Wave Life Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track WVE (Wave Life Sciences Ltd.) and more on Quantisnow.